AHR and plasma cell myeloma: Our group previously identified clofazimine (CLF), an FDA-approved antibiotic approved for drug-resistant tuberculosis and lepromatous leprosy, as a novel AhR antagonist with anti-multiple myeloma and anti-neuroblastoma efficacy (18, 70).